JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: OTF 1
Drug: OTF 2
Drug: OTF 3
Drug: OTF 4

First Posted Date: 2020-03-09

Last Posted Date: 2020-09-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 16

Registration Number: NCT04300621

Locations: 🇧🇪
SGS Life Science Services, Antwerpen, Belgium

A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-54135419

First Posted Date: 2020-02-25

Last Posted Date: 2021-09-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 17

Registration Number: NCT04282746

Locations: 🇧🇪
SGS Life Science Services, Antwerpen, Belgium

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Phase 2

Withdrawn

Conditions: Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Azacitidine
Drug: Cusatuzumab

First Posted Date: 2020-02-11

Last Posted Date: 2022-05-20

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT04264806

Locations: 🇸🇦
King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
🇨🇭
UniversitaetsSpital Zuerich, Zürich, Switzerland
🇦🇺
St Vincents Hospital Sydney, Darlinghurst, Australia

and more 70 locations

Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab

First Posted Date: 2020-02-11

Last Posted Date: 2020-07-07

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT04264884

A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-64417184

First Posted Date: 2020-02-06

Last Posted Date: 2020-09-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 16

Registration Number: NCT04258189

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Canagliflozin 100 mg
Drug: Placebo

First Posted Date: 2020-02-05

Last Posted Date: 2023-01-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 476

Registration Number: NCT04252287

Locations: 🇺🇸
University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
OSF HealthCare Cardiovascular Institute, Peoria, Illinois, United States
🇺🇸
Central Dupage Hospital, Winfield, Illinois, United States

and more 15 locations

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Combination Product: FDC of Macitentan and Tadalafil
Drug: Macitentan
Drug: Tadalafil

First Posted Date: 2020-01-21

Last Posted Date: 2020-09-30

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 62

Registration Number: NCT04235270

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Loperamide
Other: Placebo
Drug: Moxifloxacin

First Posted Date: 2020-01-13

Last Posted Date: 2022-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 66

Registration Number: NCT04225078

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-70033093
Drug: Placebo

First Posted Date: 2020-01-10

Last Posted Date: 2020-05-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 66

Registration Number: NCT04223349

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Phase 1

Active, not recruiting

Conditions: Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: JNJ-64264681

First Posted Date: 2019-12-24

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 85

Registration Number: NCT04210219

Locations: 🇵🇱
Pratia Onkologia Katowice, Katowice, Poland
🇨🇳
Chang-Gung Memorial Hospital, Kaohsiung, Kaohsiung County, Taiwan
🇬🇧
Queen Mary University of London, Charterhouse Square, United Kingdom

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy